Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.

Cancer Manag Res · 2009 · PMC3004670 · PMID 21188131

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, because of the small size of the subset of patients who had received rituximab-based treatment, the difference in this group did not reach statistical significance (CR rate of 71% vs 93%, overlapping 95% confidence intervals).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.